An­oth­er an­tibi­ot­ic mak­er bites the dust, as Tetraphase is swal­lowed for cheap

Some four years af­ter it re­port­ed its first batch of piv­otal tri­al da­ta, Tetraphase fi­nal­ly se­cured FDA ap­proval for its lead an­tibi­ot­ic, er­ava­cy­cline, for com­pli­cat­ed in­tra-ab­dom­i­nal in­fec­tions in 2018. But like many of its peers, mere­ly se­cur­ing ap­proval was on­ly the first hur­dle.

The big­ger ob­sta­cle was reap­ing the re­turns in a “bro­ken” mar­ket for an­tibi­otics. On Mon­day, the Mass­a­chu­setts-based com­pa­ny said it was be­ing ac­quired by Acel­Rx in an all-stock deal val­ued at a pal­try $14.4 mil­lion.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.